Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhib ...

Core Insights - NovaBridge Biosciences announced new data from the expanded Phase 1 dosing study for ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, to be presented at ESMO-IO 2025 [1][2] - The study successfully extended the therapeutic window for ragistomig, demonstrating strong anti-tumor efficacy and improved tolerability, including enhanced hepatic safety [2][3] - Ragistomig aims to provide new treatment options for patients resistant to checkpoint inhibitors, a significant drug class in cancer therapy [3][5] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - The company is developing a differentiated pipeline, including ragistomig and givastomig, targeting various cancers and conditions [8][9] - Ragistomig is being developed in collaboration with ABL Bio, utilizing advanced bispecific antibody technology to minimize off-tumor toxicity [5][6] Clinical Study Details - The Phase 1 study of ragistomig is ongoing in the U.S. and South Korea, with a primary focus on defining dose-limiting toxicity and adverse event profiles [5][6] - The new dosing schedule, Q6W, has shown promising results in PD-L1 non-responders, balancing safety and sustained efficacy [6][7] - Interim results, including immunological data, are expected to be presented at the upcoming ESMO-IO meeting [6][7]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Company Developments - The appointments of Dr. Rich and Dr. Quezada-Ruiz highlight Visara's commitment to developing innovative ophthalmic therapies, particularly the VIS-101 program targeting wet age-related macular degeneration (wet AMD) [2][5][12] - Dr. Rich aims to accelerate the development of new ophthalmology treatments and is focused on completing the Phase 2 study of VIS-101 [2][12] - Dr. Quezada-Ruiz brings extensive experience in retinal therapies and emphasizes the need for more durable treatment options for retinal diseases [2][10] Product Pipeline - VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO) [5][12][17] - The drug is expected to be Phase 3-ready in 2026, following the completion of its current Phase 2 study [5][12] Leadership Expertise - Dr. Rich has a strong background in ophthalmology and drug development, having previously held leadership roles in various biopharmaceutical companies [4][6][7] - Dr. Quezada-Ruiz has significant experience in the global development of retinal therapies and has held senior positions at major pharmaceutical companies [8][9][10] Strategic Vision - The appointments are part of NovaBridge's strategic transformation into a global biotech platform, showcasing its ability to attract top-tier talent in the industry [3][5] - The company aims to deliver value to shareholders through its innovative "hub-and-spoke" strategy [3]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has strategic partnerships with industry leaders, enhancing its research and development capabilities [1] Price Target Changes - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00, indicating a shift in analyst sentiment [2][5] - This decline in price target suggests potential influences from recent developments or broader market conditions affecting the biotech sector [2] Investment Considerations - Investors should monitor NovaBridge's ongoing clinical trials and strategic partnerships, as these factors could significantly impact future performance and stock valuation [3][5] - New announcements or updates from NovaBridge may provide further insights into potential stock movements [3] Comparative Analysis - In contrast, IMab has received a positive outlook from analysts, with a price target set at $8, reflecting increased optimism about its earnings prospects [4] - This comparison highlights the importance of analyst ratings and price targets in assessing biotech stocks [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in clinical trials and strategic partnerships enhancing its capabilities [1] - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past year, indicating a decline in analyst optimism [2][5] - Recent changes in the price target may be influenced by clinical trial developments, strategic partnerships, or broader market conditions affecting the biotech sector [3] Company Overview - NovaBridge is developing promising immuno-oncology agents such as givastomig, uliledlimab, and ragistomig, which are at various clinical trial stages [1] - The company has established strategic partnerships with major players like Ferring International Center SA, Bristol Myers Squibb, ABL Bio, Inc., and TJ Bio [1] Market Comparison - In contrast to NovaBridge, IMab has been upgraded to a Zacks Rank 2 (Buy), with a price target of $8, indicating increased optimism regarding its earnings potential [4] - The differing analyst views on NovaBridge and IMab highlight the varying expectations within the biotech sector [5]

Core Viewpoint - NewBridge Bio has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities acting as joint sponsors [1] Company Overview - NewBridge Bio is a biotechnology platform company established in 2016, focusing on the development of innovative precision immuno-oncology drugs [1] - The core product, Givastomig, is a novel bispecific antibody targeting CLDN18.2 and 4-1BB, applicable for gastric adenocarcinoma, biliary tract cancer, and pancreatic ductal adenocarcinoma [1] Product Development - Givastomig offers broader applicability and precise local immune activation in tumors compared to existing antibodies, potentially reducing systemic side effects [1] - The company has completed Phase I clinical trials for Givastomig and plans to initiate Phase II trials in early 2026 [1] - In addition to Givastomig, NewBridge Bio has three other clinical-stage projects, including uliledlimab, ragistomig, and VIS-101 [1]

Core Viewpoint - New Bridge Bio, established in 2016, is a global biotechnology platform company focused on developing innovative precision immuno-oncology drugs for cancer treatment, utilizing a new business model to enhance its drug pipeline through strategic collaborations and specialized subsidiaries [3][4]. Company Overview - New Bridge Bio primarily develops its proprietary drug, givastomig, a bispecific antibody targeting Claudin18.2 and 4-1BB, which is effective against various gastrointestinal malignancies including gastric, esophageal, and pancreatic cancers [3][4]. - The company aims to leverage its new business model to select and advance high-value therapeutic assets through dedicated subsidiaries, enhancing operational focus and risk management [3]. Product Details - Givastomig is designed to target tumors with low Claudin18.2 expression effectively and activates T-cells specifically at the tumor site, potentially reducing systemic side effects associated with traditional therapies [4]. - The global market for first-line treatments for gastric and esophageal adenocarcinoma (GEA), biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) is projected to grow significantly, with estimates of $8.9 billion, $1.8 billion, and $4.4 billion respectively by 2034 [5]. Clinical Development - New Bridge Bio has completed the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026, having received no objections from the FDA regarding its clinical trial plans for givastomig [5]. - The company has established a pipeline that includes three clinical-stage projects, with two focused on oncology and one in ophthalmology [5]. Financial Performance - For the fiscal year 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses due to high research and administrative expenses [6]. - The company’s revenue from licensing and collaboration was recorded at $632,000 for 2023, with total expenses amounting to $72.65 million [6].

的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對 其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NovaBridge Biosciences 新橋生物 （根據開曼群島法律註冊成立的有限公司） 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件， 即代表閣下知悉、接納並向新橋生物（「本公司」）、其聯席保薦人、整體協調人、顧問或包 銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長 登記前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出 要約或邀請，有意投資者務請僅依據呈交香港公司註冊處註冊的本公司招股章程作出投資 決定；有關文本將於發售期內向公眾刊發。 52791 \ (Project Ion_Redacted) 00b. 警告_Red ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of NovaBridge Biosciences 新橋生物 (Incorporated under the laws of the Cayman Islands with limited liability) WARNING The ...